MTAP and neoplasm: Indeed, single agent TNG462 was able todrive tumor regressions, including a complete response, in xenograftmodels representing multiple tumor types, demonstrating the potentialfor TNG462 to drive meaningful clinical responses in MTAP-deleted solid tumors.